BeiGene
TypePublic
Founded2010 (2010) in Beijing, China
Founder
HeadquartersBeijing, China, and Cambridge, Massachusetts, U.S., Basel, Switzerland,[1]
RevenueDecrease $309 million (2020) [2]
Increase $428 million (2019)[2]
$–1.658 billion (2020)[3]
$–960 million (2019)[3]
Number of employees
10,000
Websitewww.beigene.com

BeiGene is a global biotechnology company that specializes in the development of drugs for cancer treatment.[4] Founded in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in Asia, North America, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor.

History

BeiGene was founded in late 2010 by Xiaodong Wang, a Chinese-American scientist, and John V. Oyler,[5] an American entrepreneur who serves as the company's chief executive officer and chairman.[6] Wang and Oyler envisioned a biopharmaceutical company focusing on cancer treatment, with research and development both taking place in China.[5]

The founders provided part of the initial seed money and also received early backing from the American pharmaceutical company Merck & Co.[5] BeiGene established offices at the Zhongguancun Life Science Park near the National Institute of Biological Sciences, Beijing,[7] where Wang serves as director.[5]

On February 2, 2016, BeiGene had its first initial public offering (IPO) of 6.6 million shares priced at $24[8] on the Nasdaq Stock Market under the ticker symbol BGNE.[9] The company raised $182 million.[10] The IPO, managed by Goldman Sachs and Morgan Stanley, was backed by Hillhouse BGN Holdings and Baker Brothers, which together planned to purchase half the shares offered.[9] In a March 2018 follow-on offering, BeiGene raised another $758 million.[11] In August 2018, the company had another IPO when it offered a secondary listing of its shares on the Hong Kong Stock Exchange, raising $903 million in the process.[12]

In July 2017, BeiGene entered into a partnership with Celgene to continue the development and commercialization of the cancer drug BGB-A317,[13] also known as tislelizumab.[14] BeiGene also acquired Celgene's operations in China as well as the rights to commercialize Abraxane, Revlimid and Vidaza, Celgene's approved drugs in China.[15] As part of the deal, Celgene made a $150 million equity investment in BeiGene and acquired the rights for the sale of tislelizumab overseas for $263 million, with another $980 million plus royalties contingent on future sales.[16] The deal stipulated that, if Celgene began work on a competitor drug, BeiGene could buy back the rights to tislelizumab. In January 2019, Celgene was acquired by Bristol-Myers Squibb, which is developing a similar cancer immunotherapy drug, Opdivo, allowing BeiGene to regain its overseas rights to tislelizumab.[14] Celgene returned the rights to the drug in June 2019 along with a payment of $150 million to conclude the deal.[17]

In 2019, Amgen Inc. acquired 20.5% of BeiGene in a deal valued at $2.7 billion, and gained a seat on BeiGene's board of directors. In turn, BeiGene acquired the rights to commercialize three Amgen pharmaceuticals, Xgeva, Kyprolis, and Blincyto, as well as 20 others in development, investing $1.25 billion toward their research.[18]

In January 2021, BeiGene announced a collaboration and license agreement with Novartis to develop and commercialize tislelizumab in Canada, member countries of the European Union, Switzerland, Iceland, Japan, Liechtenstein, Mexico, Norway, Russia, United Kingdom, and the U.S.[19] In May 2021, BeiGene and Asieris Pharmaceuticals worked together to assess the efficacy and quality of Asieris's MetAP2 inhibitor and BeiGene's PD-L1 inhibitor for bladder cancer patients.[20] Novartis returned the rights to tislelizumab to BeiGene in September 2023.[21]

Research and development

In addition to clinical research, BeiGene's early business model involved obtaining the rights to experimental medicines shelved by other pharmaceutical companies and taking them through early clinical trials at Chinese medical schools and hospitals. Successful formulas would either be sold to or co-developed with larger drugmakers who could fund the late-stage trials.[5]

One of BeiGene's internally developed medicines is tislelizumab (BGB-A317), a PD-1 antibody or PD-L1 inhibitor that prevents cancer tumors from evading the immune system.[13] Tislelizumab is being developed as a monotherapy and for use in combination with other therapies for several types of cancer.[22] In December 2019, it was approved by National Medical Products Administration in China for the treatment of Hodgkin lymphoma.[23] In April 2020, tislelizumab was also approved in China to treat urothelial carcinoma.[24] In September 2021, the U.S. Food and Drug Administration (FDA) accepted a biologics license application for tislelizumab to treat unresectable, recurrent locally advanced or metastatic esophageal squamous cell carcinoma that has previously been treated with systemic therapy.[25]

BeiGene also developed zanubrutinib, a Bruton's tyrosine kinase inhibitor for the treatment of cancer, from a formula its scientists created in Beijing in 2012.[14] In November 2019, zanubrutinib became the first cancer drug developed in China to gain FDA approval;[26] it received accelerated approval for the treatment of mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.[27] In June 2020, the drug was also approved in China for the treatment of MCL, chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL);[28] it was then approved for the treatment of CLL[29] and SLL by the European Commission in November 2022[30] and by the FDA for the same indications in January 2023.[31] In September 2021, the FDA approved zanubrutinib to treat adults with Waldenström's macroglobulinemia, a rare non-Hodgkin lymphoma,[32] and separately granted an accelerated approval for use of the drug in the treatment of relapsed or refractory marginal zone B-cell lymphoma in patients who have been treated with an anti-CD20 regimen.[33]

References

  1. ↑ "Meet the most innovative and inventive pharmaceutical companies of 2021". Fortune. April 16, 2021. Archived from the original on 2021-04-16. Retrieved 2021-06-21.
  2. 1 2 "BeiGene Revenue 2014–2021". Macrotrends. Retrieved June 21, 2021.
  3. 1 2 "BeiGene Operating Income 2014–2021". Macrotrends. Retrieved June 21, 2021.
  4. ↑ Liu, Angus (29 April 2022). "BeiGene CEO touts 'strategic asset' in flagship US site and a fix to stock delisting risk". FiercePharma.
  5. 1 2 3 4 5 Loo, Daryl (2011-07-07). "BeiGene Brings Biotech to China". Bloomberg. Retrieved 2020-08-04.
  6. ↑ Lovelace Jr., Berkeley (2019-10-31). "Amgen takes 20% stake in Chinese biotech BeiGene for $2.7 billion". CNBC. Retrieved 2020-08-04.
  7. ↑ Yoffee, Lynn (2013-11-22). "John Oyler Aims To Build China's Genentech via Beigene". BioWorld. Retrieved 2020-08-04.
  8. ↑ "BeiGene raises $158.4 mln in second U.S. IPO to price in 2016". Reuters. 2016-02-03. Retrieved 2020-08-04.
  9. 1 2 Picker, Leslie (2016-02-03). "Editas Medicine and BeiGene Gain in Market Debuts". The New York Times. ISSN 0362-4331. Retrieved 2020-08-04.
  10. ↑ Ng, Eric (2020-07-13). "BeiGene seals jumbo deal as US investors eye China's pharma market". South China Morning Post. Retrieved 2020-08-04.
  11. ↑ Micklus, Amanda (2018-03-14). "Deals In Depth: January 2018". In Vivo. Informa. Retrieved 2020-08-04.
  12. ↑ Lau, Fiona; Zhu, Julie (2018-08-02). "Chinese biotech BeiGene raises $903 million in HK's first secondary listing under new rules: sources". Reuters. Retrieved 2020-08-04.
  13. 1 2 Grover, Divya; Pratap, Bhanu (2017-07-05). "Celgene signs deal with BeiGene for tumor cancer treatment". Reuters. Retrieved 2020-08-04.
  14. 1 2 3 Robbins, Rebecca (2019-02-13). "For BeiGene, Bristol-Celgene deal is poised to have big ripple effects". STAT. Retrieved 2020-08-04.
  15. ↑ Taylor, Nick Paul (6 July 2017). "Celgene bags Beigene PD-1 drug for $263M up front". Fierce Biotech. Retrieved 16 August 2023.
  16. ↑ Feuerstein, Adam (2017-07-06). "Celgene now owns a checkpoint inhibitor for solid tumors, but is Beigene deal too late for cancer immunotherapy race?". STAT. Retrieved 2020-08-04.
  17. ↑ Armstrong, Drew (2019-06-17). "Celgene Hands Cancer Drug Back to BeiGene, Plus $150 Million". Bloomberg. Retrieved 2020-08-04.
  18. ↑ Armstrong, Drew; Lyu, Dong (2019-10-31). "Amgen to Take $2.7 Billion Stake in BeiGene for China Growth". Bloomberg. Retrieved 2020-08-04.
  19. ↑ "Novartis Licenses BeiGene's Anti-PD-1 Agent Tislelizumab in North America, Europe, Japan". Precision Oncology News. 2021-02-26. Retrieved 2021-06-21.
  20. ↑ "Asieris and BeiGene to Test Combination Therapy for Bladder Cancer". Chinabio Today. 6 May 2021. Archived from the original on 2021-05-10. Retrieved 7 May 2021.
  21. ↑ Bonanos, Paul (19 September 2023). "As Novartis PD-1 deal ends, BeiGene sees U.S., EU as gateways to global access". BioCentury. Retrieved 27 November 2023.
  22. ↑ Desai, Jayesh; Deva, Sanjeev; Lee, Jong Seok; Lin, Chia-Chi; Yen, Chia-Jui; Chao, Yee; Keam, Bhumsuk; Jameson, Michael; Hou, Ming-Mo; Kang, Yoon-Koo; Markman, Ben (June 2020). "Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors". Journal for ImmunoTherapy of Cancer. 8 (1): e000453. doi:10.1136/jitc-2019-000453. ISSN 2051-1426. PMC 7295442. PMID 32540858.
  23. ↑ Lee, Sang Hyung; Lee, Hyun Tae; Lim, Heejin; Kim, Yujin; Park, Ui Beom; Heo, Yong-Seok (June 2020). "Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy". Biochemical and Biophysical Research Communications. 527 (1): 226–231. doi:10.1016/j.bbrc.2020.04.121. PMID 32446372. S2CID 218874092.
  24. ↑ "BeiGene's Tislelizumab Approved by China's NMPA for PD-L1 Elevated Bladder Cancer". Precision Oncology News. 2020-04-13. Retrieved 2020-08-05.
  25. ↑ Park, Brian (2021-09-13). "Tislelizumab Under Review for Esophageal Squamous Cell Carcinoma". MPR. Archived from the original on 2021-09-13. Retrieved 2021-12-08.
  26. ↑ "FDA Approves First Chinese Cancer Drug for U.S. Patient Use". Bloomberg. 2019-11-15. Retrieved 2020-08-05.
  27. ↑ Mathias, Tamara; Maddipatla, Manojna (2019-11-14). "China's BeiGene gets FDA approval for drug to treat rare form of lymphoma". Reuters. Retrieved 2020-08-05.
  28. ↑ Columbus, Gina (2020-06-03). "Zanubrutinib Gains Approval in China for Relapsed/Refractory CLL/SLL and MCL". OncLive. Retrieved 2020-08-05.
  29. ↑ "BeiGene's Brukinsa receives EC approval for chronic lymphocytic leukaemia". PMLive. 21 November 2022. Retrieved 30 June 2023.
  30. ↑ Liu, Angus (22 November 2022). "ASH: AbbVie, J&J's Imbruvica under serious threat as BeiGene's Brukinsa delivers head-to-head trial win". Fierce Pharma. Retrieved 30 June 2023.
  31. ↑ Killmurray, Conor (19 January 2023). "FDA Approves Zanubrutinib in Adult Patients with CLL/SLL". Targeted Oncology. Retrieved 30 June 2023.
  32. ↑ Mulcahy, Nick (September 2, 2021). "FDA Approval for Zanubrutinib in Waldenström's Macroglobulinemia". Medscape. Archived from the original on 2021-09-02. Retrieved 2021-12-08.
  33. ↑ Park, Brian (September 15, 2021). "Brukinsa Gets Accelerated Approval for Marginal Zone Lymphoma". MPR. Retrieved 2021-12-08.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.